Sinclair Michael 4

4 · OPIANT PHARMACEUTICALS, INC. · Filed Mar 3, 2023

Form 4

Period: 2023-03-02

Director

Transactions

Disposition to Issuer
Common Stock
2023-03-02$20.00/sh−27,450$549,000→ 0 total(indirect: Footnote)
Disposition to Issuer
Common Stock, par value $0.001 per share
2023-03-02$20.00/sh−22,720$454,400→ 0 total
Disposition to Issuer
Common Stock, par value $0.001 per share
2023-03-02$20.00/sh−40,000$800,000→ 0 total
Disposition to Issuer
Options
2023-03-02−100,000→ 0 total
Exercise: $8.00From: 2014-06-15Exp: 2024-06-14→ Common Stock, par value $0.001 per share (100,000 underlying)
Disposition to Issuer
Options
2023-03-02−250,000→ 0 total
Exercise: $7.25From: 2015-10-27Exp: 2025-10-26→ Common Stock, par value $0.001 per share (250,000 underlying)
Disposition to Issuer
Options
2023-03-02−75,000→ 0 total
Exercise: $6.00From: 2013-12-31Exp: 2023-12-30→ Common Stock, par value $0.001 per share (75,000 underlying)

Footnotes (3)

[F1]Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
[F2]27,450 shares held in certificate form indirectly by (i) Proton Therapy USA, a entity owned jointly by Dr. Sinclair and his son (5,000 shares); (ii) one pension fund (10,000 shares); (iii) a second pension fund (2,000 shares); (iv) Clearsearch Ltd., an entity who holds the shares for the benefit of Dr. Sinclair (2,650 shares); and (v) Eastkings Pension Fund, an entity which holds the shares for the benefit of Dr. Sinclair's wife (7,800 shares).
[F3]The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.

Documents

1 file